Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?

This publication has 82 references indexed in Scilit:

• Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study
  The Breast, 2013
• Place du pathologiste dans la prise en charge néoadjuvante des cancers du sein
  Annales de Pathologie, 2011
• Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline‐ and nonanthracycline‐based regimens for HER2‐positive breast cancer
  Cancer, 2011
• Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study
  Breast Cancer Research and Treatment, 2010
• A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients
  Breast Cancer Research and Treatment, 2010
• Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
  Breast Cancer Research and Treatment, 2009
• The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
  Breast Cancer Research and Treatment, 2009
• Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
  Cancer Chemotherapy and Pharmacology, 2007
• Epidemiology of basal-like breast cancer
  Breast Cancer Research and Treatment, 2007
• Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
  JAMA, 2006